Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
62.43 | 73.36 | 58.49 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(12.05) | (17.89) | (15.35) | — | |
P/B ratio |
3.74 | 5.84 | 6.74 | — | |
Price to Tangible BV |
19.40 | 0.00 | 0.00 | — | |
EV/Sales |
33.94 | 48.34 | 38.95 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(2.63) | (2.49) | (2.16) | — | |
EV/FCF |
(2.58) | (2.46) | (2.13) | — | |
Quick Ratio |
1.12 | 0.98 | 0.82 | 0.89 | |
Current Ratio |
1.16 | 1.02 | 0.87 | 0.93 | |
Net Debt/EBITDA |
6.99 | 6.23 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.11 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.04 | 0.00 | |
Operating CF/Net income |
1.22 | 0.96 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.12) | (0.13) | — | (0.42) | |
Interest Coverage |
(351.29) | (351.49) | (227.64) | — | |
Research and Development Expense of Revenue |
1,391.99% | 3,008.27% | 1,049.47% | — | |
Selling, General and Administrative Expense of Revenue |
379.87% | 1,165.84% | 373.00% | — | |
Intangible Assets out of Total Assets |
0.29 | 0.33 | 0.00 | 0.34 | |
Share Based Compensation of Revenue |
95.10% | 207.23% | 0.00% | 0.00% | |
Graham Net Nets |
0.02 | (0.05) | (0.12) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(29.07%) | (26.75%) | (29.82%) | — | |
Free Cash Flow Yield |
(21.06%) | (26.76%) | (31.20%) | — | |
Revenue per Share |
0.01 | 0.00 | 0.01 | — | |
Operating CF per Share |
(0.24) | (0.18) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.24) | (0.18) | 0.00 | 0.00 | |
Cash per Share |
1.34 | 1.10 | 0.97 | 0.00 | |
Shareholders Equity per Share |
0.77 | 0.54 | 0.41 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.77 | 0.54 | 0.41 | 0.00 | |
Free Cash Flow |
(24.30) | (17.78) | — | (20.34) | |
Working Capital |
19.32 | 2.45 | (15.56) | (8.65) | |
Capital Expenditures |
(0.10) | (0.10) | — | (0.54) | |
Net Current Asset Value |
5.73 | (15.26) | (32.97) | (27.62) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.08 | 0.21 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
15.70 | 1.22 | 1.92 | 9.48 | |
Average Payables |
1.80 | 2.76 | 2.17 | 2.61 | |
Average Assets |
248.33 | 224.24 | 117.40 | 212.56 | |
Average Common Equity |
114.21 | 90.85 | 72.85 | 67.55 |
Columns are period end dates